Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Sanofi's Exclusive Negotiations with Clayton Dubilier & Rice
Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division, Opella, to the U.S. private equity firm Clayton Dubilier & Rice (CD&R). This strategic move reflects Sanofi's ongoing efforts to optimize its portfolio and focus on core operations.
Valuation and Investment Details
The Opella business is valued at approximately €16 billion ($17.38 billion), equating to 14 times its expected EBITDA for 2024. Additionally, the French public investment bank, Bpifrance, is anticipated to acquire a stake of around 2%, further solidifying the financial backing of this transaction.
Transaction Timeline and Approvals
The proposed sale is subject to definitive agreements and customary statutory approvals. If all goes according to plan, the transaction is expected to close by the second quarter of 2025 at the earliest, marking a significant milestone for both Sanofi and CD&R.
As the negotiations progress, stakeholders will be closely monitoring the developments surrounding this transaction, given its potential impact on Sanofi's market position and future growth strategies.
